
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc. has demonstrated robust growth in its Retail segment, with revenues reaching $255 million, reflecting an 8.1% increase quarter-over-quarter and a 7.8% rise year-over-year, alongside expanding gross margins. The company is poised to deliver sustainable free cash flow (FCF), projected to nearly double to an estimated $205 million in 2025, following positive FCF generation for four consecutive quarters. Furthermore, anticipated gross margin expansion and strong year-over-year EPS growth for 2026 underscore the positive financial trajectory and potential for profitability enhancement, particularly as management focuses on these metrics in upcoming earnings discussions.
Bears say
Diebold Nixdorf Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from technological missteps, a lack of innovation, and difficulties in protecting intellectual property, all of which threaten revenues and profitability. The company's Banking segment has also witnessed a decline in gross margins, which fell to 26.8%, indicating increased pricing pressure from competition and decreased demand for its products. Furthermore, management's expectation of reducing operational expenses by $50 million annually may not fully mitigate the adverse impacts of potential tariffs, supply chain disruptions, and fluctuating currency exchange rates, thereby raising concerns about the company’s overall financial stability and liquidity.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares